Abstracts tagged "Rheumatoid Factor"

Abstract Number: 1317 • ACR Convergence 2025
The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients
Mohamed Abdelsalam¹, Maryam Lasheen², Menat Alla Ayman Ali Mahdy³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Mohamed Al-Adl⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Faculty of medicine Al-Azhar University Cairo, Nasr City, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Insomnia and rheumatoid arthritis (RA) are caught in a snowball effect, where chronic pain disrupts sleep and causes poor sleep quality, which in turn…
Abstract Number: 0689 • ACR Convergence 2025
Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment
Blaz Burja¹, Paco Welsing², Alain Lescoat³, Andreas Eisenring⁴, Anna-Maria Hoffmann-Vold⁵, Claire Leroy David⁶, Dinesh Khanna⁷, Francesco Del Galdo⁸, Michele Iudici⁹, Janet Pope¹⁰, julia Spierings¹¹, Madelon Vonk¹², Marie-Elise Truchetet¹³, Martine Clergeau¹⁴, Michael Hughes¹⁵, Susan Murphy¹⁶, Tracy Frech¹⁷, Oliver Distler¹⁸ and Muriel Elhai¹⁹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³CHU Rennes - University Rennes, Rennes, France, ⁴Patient research partners, Zurich, Switzerland, ⁵Oslo University Hospital, Oslo, Norway, ⁶Patient research partners, Sos, France, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Leeds, Leeds, United Kingdom, ⁹Division of Rheumatology, Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland, Geneva, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ¹²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹³Bordeaux University Hospital, Bordeaux, France, ¹⁴Patient research partners, Paris, France, ¹⁵Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ¹⁶Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Michigan, ¹⁷Vanderbilt University Medical Center, Nashville, TN, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁹Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland
Background/Purpose: Inflammatory joint and/or tendon involvement affects up to 30% of patients with systemic sclerosis (SSc), resulting in pain, reduced joint function, and impaired patients'…
Abstract Number: 0496 • ACR Convergence 2025
Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Mitndbaim Parra¹, Rafaela Ortega-Castro², Jerusalén Calvo³, Francisco Jose Cepas⁴, Montserrat Robustillo-Villarino⁵, Andres Zuniga-Vera⁵, Ana Martinez-Feito⁶, Chamaida Plasencia-Rodríguez⁷, Ester Costa-Moya⁸, Delia Taverner-Torrent⁸, Luis Sainz Comas⁹, Cesar Diaz-Torne⁹, Virginia Ruiz-Esquide¹⁰, Cynthia Rojas¹¹, Lourdes Martin-de la Sierra Lopez¹², Laura Jimenez-Rodriguez¹², David Velasco-Sanchez¹², Regina Fará Garcia¹³, Antonio Juan-Mas¹⁴, Marina soledad Moreno Garcia¹⁵, Ana Valeria Acosta Alfaro¹⁶, Santiago Muñoz¹⁷, Maria Martín López¹⁸, Raquel Zas¹⁹, FRANCISCO JAVIER GODOY NAVARRETE²⁰, Isabel Anon Onate²¹, Fernando Ortiz-Márquez²², Natalia Mena Vázquez²³, Paula Estrada-Alarcón²⁴, Lourdes Ladehesa²⁵, Alejandro Escudero Contreras³ and Clementina López Medina²⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁶Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁷Hospital Universitario La Paz, MADRID, Spain, ⁸Hospital Sant Joan Reus, Reus, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹¹Hospital Clinic, Barcelona, Spain, ¹²Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹³Hospital Son Llàtzer, Palma, Spain, ¹⁴Son Llazter University Hospital, Madrid, Spain, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁶Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁷Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁸Hospital ¹² de Octubre, Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Jaen University Hospital, Spain, Jaen, Spain, ²¹Hospital Universitario de Jaén, Jaén, Spain, ²²Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²⁴Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody directed against the Fc fragment of IgG that plays a key role in the development of rheumatoid arthritis…
Abstract Number: 0471 • ACR Convergence 2025
An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
Fredrik Albach¹, Ioanna Minopoulou¹, Artur Wilhelm², Robert Biesen¹, Arnd Kleyer¹, Norman Drzeniek³, Edgar Wiebe⁴, Anja Fleischmann³, Dominic Borie⁵, Vincent Casteleyn³, Tobias Alexander³, Christian Furth⁶, Jan Zernicke³, Burkhard Muche⁷, Sandra Hermann⁴, Pfeil Alexander⁸, Veronika Scholz³, Elpida Phithak³, Olaf Penack⁹, Kamran Movassaghi⁹, Eva Vanessa Schrezenmeier¹⁰, Udo Schneider³, Antonia Busse¹¹, Georg Schett¹², Ulrich Keller¹¹, Lars Bullinger⁹, Gerhard Krönke¹³, Marie Luise Hütter-Krönke¹⁴ and David Simon¹⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Kyverna Therapeutics, Emeryville, CA, ⁶Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁷Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁸Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁹Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, ¹⁰Department of Nephrology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ¹¹Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; German Cancer Consortium (DKTK) partner site Charité Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany, Berlin, ¹²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ¹⁴Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany, Berlin, ¹⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by autoreactive B cells that produce anti-citrullinated protein antibodies (ACPA), contributing to sustained synovial inflammation…
Abstract Number: 0441 • ACR Convergence 2025
Charting the Course of Worsening: Utilizing Standard Outcomes to Define Worsening for Pathophysiological Insights into RA
Charis Meng¹, Caci Julia², Kelsey Gripp², Deanna Jannat-Khah¹, Yvonne Lee³, Susan J. Bartlett⁴, Clifton Bingham⁵ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Northwestern University, Chicago, IL, ⁴McGill University, Beaconsfield, QC, Canada, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: RA disease worsening contributes to joint damage and cardiovascular disease. While measures of improvement are established in RA, we do not have uniform definitions…
Abstract Number: 0458 • ACR Convergence 2024
Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Sara Achenbach³ and Elena Myasoedova², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
Abstract Number: 2302 • ACR Convergence 2024
A Specific Molecular Profiling of Secreted Rheumatoid Factors in Sjögren’ S Disease Patients with Lymphoma
Jing Jing Wang¹, Bridie Armour¹, Alexander Troelnikov¹, Tim Chataway¹, Veronique LE GUERN², Eric Hachulla³, Alain SARAUX⁴, Claire Larroche⁵, Jacques-Eric Gottenberg⁶, Xavier Mariette⁷ and Gaetane Nocturne⁷, ¹Flinders University, Adeleide, Australia, ²Cochin hospital, Paris, France, ³University of Lille, LILLE, France, ⁴CHU Brest, Brest, France, ⁵Avicenne University Hospital, Avicenne, France, ⁶Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁷Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Sjogren’s disease (SjD) is characterized by an increased risk of lymphoma (x 10-15 compared to the general population). We and others have previously demonstrated…
Abstract Number: 0475 • ACR Convergence 2024
Rheumatoid Arthritis – Progressive Interstitial Lung Disease with Abatacept: Data from a Large National Multicenter Cohort
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Libe Ibarrola Paino³, Ivette Casafont-Sole⁴, Jesús Loarce⁵, Juan María Blanco Madrigal⁶, Santos Castañeda⁷, Rafaela Ortega-Castro⁸, Natalia Mena Vázquez⁹, Nuria Vegas Revenga¹⁰, Lucia Cristina Dominguez Casas¹¹, Cilia Peralta Ginés¹², Carolina Diez Morrondo¹³, Lorena Pérez Albadalejo¹⁴, Rubén López Sánchez¹⁵, MARIA GUADALUPE MANZANO CANABAL¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez Viejo¹⁸, Gema Bonilla¹⁹, Olga Maíz Alonso²⁰, Carmen Carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno Martinez-Losa²³, Ana Urruticoechea-Arana²⁴, Sergi Ordoñez²⁵, Carmen González Montagut²⁶, Andrea García-Valle²⁷, Juan Ramón De Dios²⁸, Patricia Carreira²⁹, Tomás Vázquez Rodríguez³⁰, Delia Fernández-Lozano³¹, Ignacio Brana Abascal³², Rafael Benito Melero-Gonzalez³³, Emilio Giner³⁴, Virginia Ruiz Esquide³⁵, Clara Ventin Rodriguez³⁶, Marina Rodriguez³⁷, Pablo Andújar-Brazal³⁸, Julia Fernandez Melon³⁹, Lilian M. López-Núñez⁴⁰, JOSE RAMON LAMUA RIAZUELO⁴¹, Carlos Fernández Díaz⁴², Javier Loricera⁴³ and Ricardo Blanco-Alonso⁴⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Rheumatology Division, Bisadoa Hospital, Bidasoa, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁹IBIMA, Málaga, Andalucia, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Hospital Universtario San Agustin, Oviedo, Spain, ¹²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹³Hospital de Leon, León, Spain, ¹⁴Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ¹⁶CAZA, Salamanca, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹⁹H. Universitario La Paz, Madrid, Spain, ²⁰3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ²¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ²⁵Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain, ²⁶Hospital Universitario de Valladolid, Valladolid, Spain, ²⁷Hospital General Río Carrión, Palencia, Spain, ²⁸Osakidetza, Vitoria, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ³⁰Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ³²Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ³³CHU Ourense, O Carballino, Spain, ³⁴Hospital Royo Villanova, Teruel, Spain, ³⁵Hospital Clinic Barcelona, Barcelona, Spain, ³⁶Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁷Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁸Hospital Universitario Doctor Peset, Valencia, Spain, ³⁹Hospital Son Espases, Palma, Spain, ⁴⁰Hospital Universitari Son Llàtzer, Palma, Spain, ⁴¹Hospital Universitario del Henares, Madrid, Spain, ⁴²Hospital Universitario Santa Lucía, Cartagena, Spain, ⁴³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
Abstract Number: 2671 • ACR Convergence 2024
Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial
Michael Weinblatt¹, Paul Emery², Vivian Bykerk³, Andrew Cope⁴, Gerd Burmester⁵, Yoshiya Tanaka⁶, Gustavo Citera⁷, Peter Nash⁸, Quentin Dornic⁹, Sheila Kelly¹⁰ and Michael Maldonado⁹, ¹Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ²University of Leeds, Leeds, United Kingdom, ³Hospital For Special Surgery, New York, NY, ⁴King's College London, London, United Kingdom, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁷Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁸Griffith University, Brisbane, Australia, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bristol Myers Squibb, Doylestown, PA
Background/Purpose: For patients (pts) early in their RA disease course, with a clinical profile characterized by inadequate response to MTX (MTX-IR), high titers of ACPA…
Abstract Number: 0488 • ACR Convergence 2024
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Pablo Martínez Calabuig¹, Elena Grau García², Samuel Leal Rodriguez², Ernesto Tovar Sugrañes³, José Ivorra-Cortés⁴, Carmen Riesco Barcena³, Anderson Huaylla Quispe³, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro³, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado³ and Jose A Román-Ivorra⁹, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
Abstract Number: 0498 • ACR Convergence 2024
ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jacob Welch¹, Yangyuna Yang¹, Joshua Baker², Katherine Wysham³, Dana Ascherman⁴, Paul Monach⁵, Gail Kerr⁶, Andreas Reimold⁷, grant Cannon⁸, Gary Kunkel⁹, William Robinson¹⁰, Michael Duryee¹, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵VA Boston Healthcare System, Boston, MA, ⁶Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁷Dallas VA Medical Center, Dallas, TX, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹⁰Stanford University, Palo Alto, CA
Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for…
Abstract Number: 0511 • ACR Convergence 2024
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Josef Smolen¹, Ted Mikuls², James Galloway³, Ulf Müller-Ladner⁴, Jeffrey Curtis⁵, Motomu Hashimoto⁶, Tsutomu Takeuchi⁷, Ernest Choy⁸, Yoshiya Tanaka⁹, Carlos Cara¹⁰, Bernard Lauwerys¹¹, Nicola Tilt¹², Baran Ufuktepe¹³ and Peter C. Taylor¹⁴, ¹Medical University of Vienna, Vienna, Austria, ²University of Nebraska Medical Center, Omaha, NE, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴Justus-Liebig University Giessen, Bad Nauheim, Germany, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶Osaka Metropolitan University, Osaka, Japan, ⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁸Cardiff University School of Medicine, Cardiff, United Kingdom, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰UCB Pharma, Madrid, Spain, ¹¹UCB Pharma, Brussels, Belgium, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Istanbul, Turkey, ¹⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: In pts with RA, high RF levels are associated with poor prognosis, higher disease activity, and decreased response to monoclonal antibodies targeting tumor necrosis…
Abstract Number: 0777 • ACR Convergence 2024
Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients
Theodoros Ioannis Papadimitriou¹, Jing Jing Wang², Xuehui He³, Sidney van der Zade⁴, Massis Krekorian⁵, Prashant Singh⁶, Erik Dik⁵, Ger Pruijn⁵, Tom Gordon², Hans Koenen⁷, Martijn Huijnen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Flinders University, Adeleide, Australia, ³Radboudumc, Nijmegen, Netherlands, ⁴Radboudumc, Amsterdam, Netherlands, ⁵Radboudumc, Nijmegen, Gelderland, Netherlands, ⁶Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands
Background/Purpose: Sjögren’s syndrome (SjS) is a chronic inflammatory disorder, characterized by formation of autoantibodies. Over time rheumatoid factor (RF) clones can give rise to cryoglobulinemic…
Abstract Number: 1009 • ACR Convergence 2024
Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept
Kevin Winthrop¹, Jeremy Hawkins², Adriana Weinberg³, Sarah Siegel², Jessica Baxter³, Krystle Garth³, Joseph Huffstutter⁴, James Loveless⁵, Suzanne gharib⁶, Shanmugapriya (Priya) Reddy⁷, Jayashree Sinha⁸, Elvia Moreta⁹, David Ridley¹⁰, Ilhem Messaoudi¹¹ and Jeffrey Curtis¹², ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³University of Colorado, Aurora, CO, ⁴Arthritis Associates PLLC, Signal Mountain, TN, ⁵St Luke's Health System, Boise, ID, ⁶Charleston Area Medical Center, Charleston, MD, ⁷Southwest Florida Rheumatology, Riverview, FL, ⁸self employed, Clovis, NM, ⁹St. Paul Rheumatology, Eagan, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹University of Kentucky, Lexington, ¹²University of Alabama at Birmingham, Hoover, AL
Background/Purpose: The adjuvanted recombinant glycoprotein E (gE) herpes zoster vaccine (RZV) received expanded approval for use in 2021 for adults receiving immunosuppression. Despite approval, little…
Abstract Number: 1388 • ACR Convergence 2024
CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis
Ting Wang¹, Ryan Stultz¹, Natalia Giltiay², Christian Lood¹ and Bobby Kwanghoon Han¹, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, USA, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). We conducted this study to identify novel predictive and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].